AER 1101474 is a spontaneous case was received on 10/Aug/2012 from a physician via company representative 
and concerns a female patient of unknown age who experienced suspected progressive multifocal 
leukoencephalopathy while being treated with rituximab (Mabthera).
No past medical history and concurrent conditions were reported. No concomitant medications and past drugs were
reported.
On an unspecified date, the patient started therapy with rituximab (dose, frequency, route and form: not reported) 
for an unknown indication. On an unspecified date, the patient  experienced progressive multifocal 
leukoencephalopathy.
At the time of this report, the outcome of event suspected  progressive multifocal leukoencephalopathy and therapy
status for rituximab was not reported.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 482 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The reporter did not assess the causal relationship for event suspected  progressive multifocal 
leukoencephalopathy with rituximab.
The company assessed the event of suspected  progressive multifocal leukoencephalopathy as medically 
significant.
No further information was provided.
Additional information was received on 20/Oct/2014. The following information was added to the case: The 
physician was not working in the hospital anymore where the patient was treated and he had not sent any fup 
information. (Lost to follow-up)